Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C19H30O3 |
Molecular Weight | 306.4397 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@]1(O)CC[C@H]2[C@@H]3CC[C@H]4CC(=O)OC[C@]4(C)[C@H]3CC[C@]12C
InChI
InChIKey=QSLJIVKCVHQPLV-PEMPUTJUSA-N
InChI=1S/C19H30O3/c1-17-11-22-16(20)10-12(17)4-5-13-14(17)6-8-18(2)15(13)7-9-19(18,3)21/h12-15,21H,4-11H2,1-3H3/t12-,13+,14-,15-,17-,18-,19-/m0/s1
Molecular Formula | C19H30O3 |
Molecular Weight | 306.4397 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 7 / 7 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/oxandrolone.html Mosby, M.H. (2015) "Mosby's Drug Reference for Health Professions", p.1205 Retrieved from https://books.google.ru/books?id=IuF1BwAAQBAJ
Curator's Comment: description was created based on several sources, including:
https://www.drugs.com/pro/oxandrolone.html Mosby, M.H. (2015) "Mosby's Drug Reference for Health Professions", p.1205 Retrieved from https://books.google.ru/books?id=IuF1BwAAQBAJ
Oxandrolone is a synthetic, orally active anabolic-androgenic steroid. Oxandrolones interact with androgen receptors in target tissues. Oxandrin is indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis. Side effects include: elevated aminotransferases (ALT, AST), lipid abnormalities (e.g., decreased HDL cholesterol concentrations). Cardiovascular side effects have included edema, with and without congestive heart failure. Oxandrolone may inhibit the metabolism of oral hypoglycemic agents. In patients with edema, concomitant administration with adrenal cortical steroids or ACTH may increase the edema.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1871 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15219414 |
62.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Palliative | OXANDRIN Approved UseOxandrolone is indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis (See DOSAGE AND ADMINISTRATION). Launch Date1964 |
|||
Secondary | OXANDRIN Approved UseOxandrolone is indicated as adjunctive therapy to promote weight gain after weight loss following extensive surgery, chronic infections, or severe trauma, and in some patients who without definite pathophysiologic reasons fail to gain or to maintain normal weight, to offset the protein catabolism associated with prolonged administration of corticosteroids, and for the relief of the bone pain frequently accompanying osteoporosis (See DOSAGE AND ADMINISTRATION). Launch Date1964 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
23 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32265605/ |
0.2 mg/kg single, buccal dose: 0.2 mg/kg route of administration: Buccal experiment type: SINGLE co-administered: |
OXANDROLONE plasma | Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN |
|
44.6 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32265605/ |
10 mg single, buccal dose: 10 mg route of administration: Buccal experiment type: SINGLE co-administered: |
OXANDROLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
15.1 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32265605/ |
0.1 mg/kg 2 times / day multiple, buccal dose: 0.1 mg/kg route of administration: Buccal experiment type: MULTIPLE co-administered: |
OXANDROLONE plasma | Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN |
|
417 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4729902 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXANDROLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
58.6 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32265605/ |
0.2 mg/kg single, buccal dose: 0.2 mg/kg route of administration: Buccal experiment type: SINGLE co-administered: |
OXANDROLONE plasma | Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN |
|
249 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32265605/ |
10 mg single, buccal dose: 10 mg route of administration: Buccal experiment type: SINGLE co-administered: |
OXANDROLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
|
36.9 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32265605/ |
0.1 mg/kg 2 times / day multiple, buccal dose: 0.1 mg/kg route of administration: Buccal experiment type: MULTIPLE co-administered: |
OXANDROLONE plasma | Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN |
|
3380 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4729902 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXANDROLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
2.87 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32265605/ |
0.2 mg/kg single, buccal dose: 0.2 mg/kg route of administration: Buccal experiment type: SINGLE co-administered: |
OXANDROLONE plasma | Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN |
|
2.19 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32265605/ |
0.1 mg/kg 2 times / day multiple, buccal dose: 0.1 mg/kg route of administration: Buccal experiment type: MULTIPLE co-administered: |
OXANDROLONE plasma | Homo sapiens population: UNHEALTHY age: NEWBORN sex: FEMALE / MALE food status: UNKNOWN |
|
9.4 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4729902 |
10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered: |
OXANDROLONE plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: |
unhealthy, 39.5+/-7.5 Health Status: unhealthy Age Group: 39.5+/-7.5 Sex: M+F Sources: |
Disc. AE: Aspartate aminotransferase increased, ALT increased... Other AEs: Aspartate aminotransferase increased, ALT increased... AEs leading to discontinuation/dose reduction: Aspartate aminotransferase increased (grade 3-4) Other AEs:ALT increased (grade 3-4) Aspartate aminotransferase increased (grade 3-4, 14.8%) Sources: ALT increased (grade 3-4, 14.8%) |
5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Disc. AE: Peliosis hepatis, Liver failure... AEs leading to discontinuation/dose reduction: Peliosis hepatis Sources: Liver failure Hepatocellular carcinoma High density lipoprotein decreased Low density lipoprotein increased Atherosclerosis Coronary artery disease |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
ALT increased | grade 3-4, 14.8% | 80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: |
unhealthy, 39.5+/-7.5 Health Status: unhealthy Age Group: 39.5+/-7.5 Sex: M+F Sources: |
Aspartate aminotransferase increased | grade 3-4, 14.8% | 80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: |
unhealthy, 39.5+/-7.5 Health Status: unhealthy Age Group: 39.5+/-7.5 Sex: M+F Sources: |
ALT increased | grade 3-4 Disc. AE |
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: |
unhealthy, 39.5+/-7.5 Health Status: unhealthy Age Group: 39.5+/-7.5 Sex: M+F Sources: |
Aspartate aminotransferase increased | grade 3-4 Disc. AE |
80 mg 1 times / day multiple, oral Highest studied dose Dose: 80 mg, 1 times / day Route: oral Route: multiple Dose: 80 mg, 1 times / day Sources: |
unhealthy, 39.5+/-7.5 Health Status: unhealthy Age Group: 39.5+/-7.5 Sex: M+F Sources: |
Atherosclerosis | Disc. AE | 5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Coronary artery disease | Disc. AE | 5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Hepatocellular carcinoma | Disc. AE | 5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
High density lipoprotein decreased | Disc. AE | 5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Liver failure | Disc. AE | 5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Low density lipoprotein increased | Disc. AE | 5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
Peliosis hepatis | Disc. AE | 5 mg 4 times / day multiple, oral Recommended Dose: 5 mg, 4 times / day Route: oral Route: multiple Dose: 5 mg, 4 times / day Sources: |
unhealthy Health Status: unhealthy Sources: |
PubMed
Title | Date | PubMed |
---|---|---|
Anabolic agents and wound healing. | 2001 May-Jun |
|
Aspects of the treatment of Turner syndrome. | 2001 Oct |
|
Exercise treatment for HIV-associated metabolic and anthropomorphic complications. | 2001 Oct |
|
A pilot randomized trial of oxandrolone in inclusion body myositis. | 2002 Apr 9 |
|
Favorable final height outcome in girls with Ullrich-Turner syndrome treated with low-dose growth hormone together with oxandrolone despite starting treatment after 10 years of age. | 2002 Feb |
|
Corticosteroids in Duchenne muscular dystrophy: a reappraisal. | 2002 Mar |
|
Body cell mass repletion and improved quality of life in HIV-infected individuals receiving oxandrolone. | 2002 Nov-Dec |
|
Anabolic treatment with GH, IGF-I, or anabolic steroids in patients with HIV-associated wasting. | 2002 Sep |
|
Androgen therapy in constitutional delay of growth. | 2003 |
|
Nutritional and pharmacological support of the metabolic response to injury. | 2003 Apr |
|
Improved net protein balance, lean mass, and gene expression changes with oxandrolone treatment in the severely burned. | 2003 Jun |
|
Relationship between body composition and cytokines in cachectic patients with chronic obstructive pulmonary disease. | 2003 Jun |
|
Growth and puberty in Turner's syndrome. | 2003 Mar |
|
Drug increases lean tissue mass in patients with cancer. | 2003 Mar |
|
Reversible azoospermia: anabolic steroids may profoundly affect human immunodeficiency virus-seropositive men undergoing assisted reproduction. | 2003 May |
|
The anabolic androgenic steroid oxandrolone in the treatment of wasting and catabolic disorders: review of efficacy and safety. | 2004 |
|
Nutrition intervention is beneficial in oncology outpatients receiving radiotherapy to the gastrointestinal or head and neck area. | 2004 Aug 2 |
|
Screening of free 17-alkyl-substituted anabolic steroids in human urine by liquid chromatography-electrospray ionization tandem mass spectrometry. | 2004 Feb |
|
The long-term effect of oxandrolone on hepatic acute phase proteins in severely burned children. | 2004 Jan |
|
Treatment guidelines for HIV-associated wasting. | 2004 Jan-Feb |
|
The right mix: using nutritional interventions and an anabolic agent to manage a stage IV ulcer. | 2004 Jan-Feb |
|
Support of the metabolic response to burn injury. | 2004 Jun 5 |
|
Comparing megestrol acetate therapy with oxandrolone therapy for HIV-related weight loss: similar results in 2 months. | 2004 Mar 15 |
|
[Carbohydrate metabolism in patients with Turner syndrome. The effect of therapy with growth hormone, oxandrolone and a combination of both]. | 2005 |
|
A comparison of the clinical and cost-effectiveness of 3 intervention strategies for AIDS wasting. | 2005 Apr 1 |
|
Screening of anabolic steroids in horse urine by liquid chromatography-tandem mass spectrometry. | 2005 Apr 29 |
|
Six-week improvements in muscle mass and strength during androgen therapy in older men. | 2005 Dec |
|
Longitudinal monitoring of bone measured by quantitative multisite ultrasound in patients with Crohn's disease. | 2005 Feb |
|
Metacarpophalangeal pattern profile analysis as a tool for early diagnosis of Turner syndrome. | 2005 Jul |
|
Final height in a patient with Laron syndrome after long-term therapy with rhlGF-I and short-term therapy with LHRH-analogue and oxandrolone during puberty. | 2005 Mar |
|
Influence of hormonal therapy on growth rate and bone age progression in patients with Turner syndrome. | 2005 Mar-Apr |
|
Post burn muscle wasting and the effects of treatments. | 2005 Oct |
|
Corticosteroid-induced myopathy in spinal cord injury patients: a role for anticatabolic agents? | 2006 Apr |
|
The current status of treatment for inclusion-body myositis. | 2006 Jan 24 |
|
Advances in burn critical care. | 2006 Sep |
Patents
Sample Use Guides
The daily adult dosage is 2.5 mg to 20 mg given in 2 to 4 divided doses. The desired response may be achieved with as little as 2.5 mg or as much as 20 mg daily. A course
of therapy of 2 to 4 weeks is usually adequate.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/10077001
Dimerization and DNA binding of the AR fragments were observed at 0.5–1 uM
oxandrolone.
Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:47:18 GMT 2025
by
admin
on
Mon Mar 31 17:47:18 GMT 2025
|
Record UNII |
7H6TM3CT4L
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-VATC |
QA14AA08
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
||
|
WIKIPEDIA |
Designer-drugs-Oxandrolone
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
||
|
FDA ORPHAN DRUG |
45790
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
||
|
FDA ORPHAN DRUG |
103797
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
||
|
NCI_THESAURUS |
C243
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
||
|
FDA ORPHAN DRUG |
59091
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
||
|
DEA NO. |
4000
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
||
|
NCI_THESAURUS |
C2360
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
||
|
LIVERTOX |
719
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
||
|
FDA ORPHAN DRUG |
45590
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
||
|
WHO-ATC |
A14AA08
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
||
|
FDA ORPHAN DRUG |
75793
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
53-39-4
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
5878
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
7H6TM3CT4L
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
67068
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
200-172-9
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
7092
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
1482003
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
7820
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
DB00621
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
3373
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
DTXSID8023399
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
7779
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | RxNorm | ||
|
100000083029
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
OXANDROLONE
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
C29306
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
7H6TM3CT4L
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
CHEMBL1200436
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
SUB09496MIG
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
1325
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
D010074
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
2011
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | |||
|
m8290
Created by
admin on Mon Mar 31 17:47:18 GMT 2025 , Edited by admin on Mon Mar 31 17:47:18 GMT 2025
|
PRIMARY | Merck Index |
Related Record | Type | Details | ||
---|---|---|---|---|
|
BASIS OF STRENGTH->SUBSTANCE |
ASSAY (HPLC)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
||
|
IMPURITY -> PARENT |
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |